Analyst firms · H.C. Wainwright · PRME

H.C. Wainwright PRME price target and rating history

Prime Medicine Inc. (PRME) · Health Care

H.C. Wainwright rates Prime Medicine Inc. (PRME) Buy with a $8 price target, as of its latest action on Jun 29, 2026. It has published 3 rating actions on PRME since May 2024, including 1 upgrade and 1 downgrade. Across 4 firms with a PRME price target in the last 12 months, the median target is $8.50. H.C. Wainwright's $8 is 6% below that.

Current rating
Buy
Price target
$8
Median target, all firms
$8.50
Actions on PRME
3

H.C. Wainwright price target on PRME

$10$9$820252026
H.C. Wainwright price target on PRME, each point a stated target, May 2024 to June 2026.

Every H.C. Wainwright rating on PRME

How other firms rate PRME

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Chardan Capital MarketsBuy$7Aug 25, 2026
BMO Capital MarketsOutperform$9Aug 19, 2026
H.C. WainwrightBuy$8Jun 29, 2026
OppenheimerOutperform$11Mar 12, 2026

Questions about H.C. Wainwright and PRME

What is H.C. Wainwright's price target for PRME?
H.C. Wainwright's latest stated price target for Prime Medicine Inc. (PRME) is $8, from its action on Jun 29, 2026.
What is H.C. Wainwright's rating on PRME?
H.C. Wainwright rates PRME Buy, a bullish rating, as of Jun 29, 2026.
When did H.C. Wainwright last change its view on PRME?
On Jun 29, 2026, H.C. Wainwright upgrades to Buy from Neutral, price target $8.
How does H.C. Wainwright's PRME target compare with other analysts?
Across 4 firms with a PRME price target in the last 12 months, the median target is $8.50. H.C. Wainwright's $8 is 6% below that.

More PRME rating histories

All H.C. Wainwright ratingsPRME news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.